Oral Program

Sunday, 26 October 2014		
08:00-09:00	Registration	
Room	**Garden Room**	
09:00-12:30	**Opening Session & Plenary Session 1** *Session Chair: Adolfo Garcia-Sastre & Margaret Liu*	
09:00-09:10	Opening Remarks: Adolfo Garcia-Sastre and Ted M. Ross, Congress Co-Chairs	
09:10-09:40	**[K01] Recent scientific and clinical advances in Sanofi Pasteur's dengue vaccine program** S. Gurunathan*, N. Jackson, *Sanofi-Pasteur-France, France*	
09:40-10:10	**[K02] The road from concept to proof of principle to deployment of the PfSPZ vaccine for elimination of plasmodium falciparum malaria** S.L. Hoffman, *Sanaria Inc, USA*	
10:10-10:40	**[K03] Immune responses in preinvasive HPV disease: Going to the target site to get answers** C. L. Trimble, *Johns Hopkins Hospital, USA*	
10:40-11:00	**Refreshment Break** *Room: Grand Ballroom I-III*	
11:00-11:30	**[K04] Progress in TB vaccine development** H. McShane, *University of Oxford, UK*	
11:30-12:00	**[K05] Prospects for prevention of meningococcal serogroup B disease with a bivalent fHBP vaccine** K.U. Jansen*, J. Perez, J. Eiden, S.L. Harris, T.R. Jones, L. York, A. Anderson, *Pfizer Vaccine Research and Development, USA*	
12:00-12:30	**[K06] Creating an innovative vaccine pipeline** C. W. Mandl, *Novartis Vaccines, USA*	
12:30-13.30	**Lunch** *Room: Grand Ballroom I-III*	
Room	**Garden Room**	**Borghese Garden/Salon Venezia**
13:30-15:25	**Breakout Session 1: Bacterial Vaccines** *Session Chair: Olaf Schneewind & David Weiner*	**Breakout Session 2: Vaccines against Viral Pathogens** *Session Chair: Stephen Hoffman & Connie Schmaljohn*
13:30-13:50	**[B1.1] Guinea pig, a model organism for infectious diseases, provides additional insights in a vaccine design against *S. aureus*** H.K. Kim*[1,2], F. Falugi[1,2], L. Thomer[1,2], N. Ciletti[2], D. Missiakas[1,2], O. Shcneewind[1,2], [1]*University of Chicago, USA,* [2]*Howard Taylor Ricketts Laboratory, USA*	**[K08] Phase 1 clinical studies of DNA vaccines for hantaviruses and alphaviruses** C.S. Schmaljohn*[1], J.W. Hooper[1], L.C. Dupuy[1], D. Hannaman[2], [1]*Army Medical Research Institute of Infectious Diseases, USA,* [2]*Ichor Medical Systems, Inc., USA*
13:50-14:10	**[K07] A role of follicular helper T cells on effects of oral bacteria-based vaccine** M-N Kweon, *University of Ulsan College of Medicine/Asan Medical Center, Republic of Korea*	**[K09] Potential and limitations of modified-live herpesvirus vaccines** N. Osterrieder, *Freie Universität Berlin, Germany*
14:10-14:25	**[B1.2] Live attenuated enterotoxigenic *Escherichia coli* (ETEC) vaccine candidate protects against virulent ETEC in a human ETEC challenge model** C. Harro*[1], S. Chakraborty[1], D. Sack[1], B. DeNearing[1], L. Bourgeois[2], M. Darsley[3], N. Bauers[2], L. Dally[4], A. Fix[2], R. Walker[2], [1]*The Johns Hopkins Bloomberg School of Public Health, USA,* [2]*PATH, USA,* [3]*MD Biologic Consulting, UK,* [4]*The EMMES Corporation, USA*	**[B2.1] 2014 guinea ebola virus recombinant glycoprotein (GP) nanoparticle vaccine was highly immunogenic and cross-neutralized 1976 ebola virus GP pseudovirus** G. Smith[1], Y. Liu[1], D. Flyer[1], L. Fries[1], J. Hooper[2], G. Glenn[1], [1]*Novavax Inc,* [2]*Virology Division*
14:25-14:40	**[B1.3] Single intranasal dose of AdVAV™ is non-inferior to two-doses of BioThrax® vaccine in a *B.***	**[B2.2] First clinical results of novel Chikungunya vaccine tested in phase 1/2 trial: Safety and**

	***anthracis* aerosolized spore challenge model in NZW rabbits** M.S. Roberts*[1], B.A. Andersen[1], T. Krubit[1], V. Krishnan[1], G.S. Sivko[2], G.V. Stark[2], J. Zhang[1], T. Feng[1], V.A. Haque[1], M.G. Duchars[1], *[1]Vaxin Inc., USA, [2]Battelle, USA, [3]Genie Bio-Logic, USA*	**immunogenicity data** K. Ramsauer*[1], R.J. Putnak[2], P. Despres[3], C. Firbas[4], M. Müllner[1], F. Tangy[3], S.J. Thomas[2], E. Tauber[1], *[1]Themis Bioscience GmbH, Austria, [2]Viral Diseases Branch, USA, [3]Institute Pasteur, France, [4]Medical University of Vienna, Austria*
14:40-14:55	**[B1.4] An optimized, synthetic DNA vaccine encoding the toxin A and toxin B Receptor binding domains of Clostridium difficile induces protective antibody responses In Vivo** M.A. Kutzler*[1], S.M. Baliban[1], A. Michael[1], A. Khan[2], N.Y. Sardesai[2], S. Cocklin[1], L. Bouillaut[3], B.P. Latimer[1], P. Marx[4], D.B. Weiner[5], *[1]Drexel University College of Medicine, USA, [2]Inovio Pharmaceuticals, USA, [3]Tufts University School of Medicine, USA, [4]Tulane National Primate Research Center, USA, [5]University of Pennsylvania School of Medicine, USA*	**[B2.3] Essential role for autophagy in the maintenance of immunological memory against influenza infection** M. Chen, M.J. Hong, H. Sun, L. Wang, X. Shi, B.E. Gilbert, D.B. Corry, F. Kheradmand, J. Wang*, *Baylor College of Medicine, USA*
14:55-15:10	**[B1.5] Characterization of the *burkholderia mallei* Δ*tonB* mutant and its potential as a live attenuated vaccine** T. Mott*, S. Viajayakumar, E. Sbrana, J. Endsley, A. Torres, *University of Texas Medical Branch, USA*	**[B2.4] HSV-2 glycoproteins C, D, and E as a trivalent subunit antigen vaccine for prevention and treatment of genital herpes** S. Awasthi*, C.E. Shaw, H.M. Friedman, *Infectious Disease Division, Department of Medicine, Perelman School of Medicine, Philadelphia, PA. 19104, USA*
15:10-15:25	**[B1.6] Development of Pneumococcal surface protein antigen (PspA) based Pneumonia vaccine showing enhanced protective immunity when conjugated to Vi polysaccharide from *Salmonella typhi*** N. Kothari*[1,2], K. Genschmer[1], *[1]Internaional Vaccine Institute, Republic of Korea, [2]Sungkyungkwan University, Republic of Korea, [3]University of Alabama, USA*	**[B2.5] Immunogenicity of the RSV F nanoparticle vaccine in humans and induction of palivizumab competing antibodies: Review of immunogenicity data from 4 recent clinical trials** G.M. Glenn, *Novavax, USA*
15:25-15:50	**Refreshment Break** *Room: Grand Ballroom I-III*	
Room	**Garden Room**	
15:50-18:00	**Plenary Session 2: Respiratory Viral Vaccines** *Session Chair: Shan Lu & Scott Hensley*	
15:50-16:10	**[K10] Recent influenza vaccine advances and prospects for improved or universal influenza vaccines** R.C. Huebner, *Influenza Division Biomedical Advanced Research and Development Authority, USA*	
16:10-16:30	**[K11] Universal Influenza Vaccines: Prevention of infection against matched and mismatched strains** H. Kleanthous*[1], T. Alefantis[1], S. Anderson[1], T. Vogel[1], C.J. Crevar[2], D.M. Carter[2], R. Oomen[1], M. Parrington[1], T.M. Ross[2], *[1]Sanofi-Pasteur Inc., USA, [2]Vaccine and Gene Therapy Institute of Florida, USA*	
16:30-16:45	**[O2.1] Catching a moving target: A universal influenza virus vaccine strategy based on the conserved stalk domain of the hemagglutinin** F. Krammer*, I. Margine, R. Nachbagauer, N. Pica, R. Hai, R.A. Albrecht, A. García-Sastre, P. Palese, *Icahn School of Medicine at Mount Sinai, USA*	
16:45-17:00	**[O2.2] Sequential infection with seasonal H1N1 viruses elicits HA stem-specific antibodies.** G.A. Kirchenbaum*[1], D.M. Carter[1], F. Krammer[2], T.M. Ross[1], *[1]Vaccine and Gene Therapy Institute of Florida, USA, [2]Icahn School of Medicine at Mount Sinai, USA*	
17:00-17:15	**[O2.3] Influenza virus antigenic drift and the challenges of selecting seasonal vaccine strains for humans** S.E. Hensley, *Wistar Institute, USA*	
17:15-17:30	**[O2.4] Seasonal influenza vaccine effectiveness among the community-dwelling elderly: Meta-analysis of test-negative design case-control studies** M. Darvishian*[1,2], M.J. Bijlsma[2], E. Hak[1,2], E.R. van den Heuvel[1], *[1]Department of Epidemiology, University*	

	Medical Center Groningen, University of Groningen, The Netherlands, [2]Unit of PharmacoEpidemiology & PharmacoEconomics (PE2), Department of Pharmacy, University of Groningen, The Netherlands	
17:30-17:45	**[O2.5] Influence of pre-existing hemagglutination inhibition titers against historical influenza strains on antibody response to inactivated trivalent influenza vaccine in adults 50-80 years of age** T.M. Ross[1,5], C.J. Lin[1], M.P. Nowalk[1], H.H. Huang[1], S.M. Spencer[4], D.K. Shay[4], S. Sambhara[4], M.E. Sundaram[2], T. Friedrich[3,7], R.K. Zimmerman*[1], *[1]University of Pittsburgh, USA, [2]Marshfield Clinic Research Foundation, USA, [3]University of Wisconsin, USA, [4]Centers for Disease Control and Prevention, USA, [5]Vaccine & Gene Therapy Institute of Florida, USA, [6]UPMC St. Margaret's Family Medicine Residency, USA, [7]Wisconsin National Primate Research Center, USA*	
17:45-18:00	**[O2.6] Broad immune response induced by plant-made influenza VLP vaccines** B.J. Ward*[1], S. Trépanier[2], S. Pillet[1,2], E. Aubin[2], N. Charland[2], N. Landry[2], *[1]Research Institute of the McGill University Health Centre University, Canada, [2]Medicago Inc., Canada*	
18:00-19:30	**Poster Session 1 & Welcome Drinks Reception** *Room: Grand Ballroom I-III*	
Monday, 27 October 2014		
08:00-08:30	Congress Registration	
Room	**Garden Room**	
08:00-08:30	**Twists and Turns: Ebola Virus and a Vaccine** Nancy J. Sullivan, *National Institutes of Health Vaccine Research Center*	
08:30- 10:35	**Plenary Session 3: Vaccine Strategies For the World** *Session Chair: Matthias Schnell & Paul Offit*	
08:30-08:55	**[K12] The Philadelphia measles epidemic of 1991: Lessons from the past** P.A. Offit[1,2], *[1]Vaccine Education Center at the Children's Hospital of Philadelphia, USA, [2]University of Pennsylvania School of Medicine, USA*	
08:55-09:20	**[K13] RSV prophylaxis for at risk groups** T.L. Villafana, *Harvard School of Public Health, USA*	
09:20-09:35	**[O3.1] A novel subunit vaccine boosts BCG-induced protective immunity and is effective in pre- and post-exposure murine model of tuberculosis** C. Counoupas*[1], R. Pinto[1], W. Britton[1,2], J. Triccas[1], *[1]University of Sydney, Australia, [2]The Centenary Institute, Australia*	
09:35-09:50	**[O3.2] Multiclade E-DNA prime enhances the functional antibody response induced by a recombinant gp120 boost in rabbits and non-human primates** M. Wise[1], N.A. Hutnick[1], J. Pollara[2], S. Wang[4], S. Lu[4], G. Ferrari[2], D. Montefiori[2], N. Sardeasi[3], D. Weiner*[1], *[1]University Of Pennsylvania, USA, [2]Duke University, USA, [3]Inovio Pharmaceuticals, USA, [4]University of Massachusetts, USA*	
09:50-10:05	**[O3.3] Rhabdoviral-based vaccine platform against Henipaviruses** D. Kurup*[1], C. Wirblich[1], A. Marzi[2], H. Feldmann[2], M.J. Schnell[1], *[1]Thomas Jefferson University, USA, [2]Laboratory of Virology, Division of Intramural Research, NIH/NIAID, USA*	
10:05-10:20	**[O3.4] Reconstructed virus seeds for a PER.C6® based inactivated poliovirus vaccine** D. Edo-Matas, B.P. Sanders*, V. van Hoek, N. Papic, I. de los Rios, A. Luitjens, J. Custers, H. Schuitemaker, *Crucell - Janssen, The Netherlands*	
10:20-10:35	**[O3.5] Impact of rotavirus vaccination on all-cause diarrhoeal hospitalisations among children under five years of age in Soweto, South Africa** M.J. Groome*[1], A. Izu[1], S. Nzenze[1], U.D. Parashar[2], S.A. Madhi[1,3], E.R. Zell[4], *[1]University of the Witwatersrand, South Africa, [2]Centers for Disease Control and Prevention, USA, [3]National Institute for Communicable Diseases, South Africa, [4]Stat-Epi Associates Inc, USA*	
10:35-11:00	**Refreshment Break** *Room: Grand Ballroom I-III*	
Room	**Garden Room**	**Borghese Garden/ Salon Venezia**
11:00-12:40	**Breakout Session 3: Veterinary Vaccines** *Session Chair: Polly Roy & Volker Gerdts*	**Breakout Session 4: Immunomodulators: Japanese Society of Vaccines** *Session Chair: Ken Ishi & Sho Yamasaki*
11:00-11:20	**[K14] RSV Vaccination: Success with novel adjuvant**	**[K16] New mechanism of action and potential**

	and delivery systems L. Babiuk[1], V. Gerdts*[2], S. van Drunen Littel-van den Hurk[1], *[1]University of Alberta, Canada, [2]University of Saskatchewan, Canada*	**biomarkers for vaccine adjuvant** K. Ishii, *National Institute of Biomedical Innovation, Japan*
11:20-11:40	**[K15] Improvement of a DNA vaccine against BoHV-1 using chemical and molecular adjuvants** V. Quattrocchi, *Institute of Virology, Argentina*	**[K17] Recognition of mycobacterial adjuvants through C-type lectin receptors** S. Yamasaki, *Kyushu University, Japan*
11:40-11:55	**[B3.1] Farm-specific monovalent/bivalent vaccination for treatment, control and eradication of virulent footrot in sheep flocks in Australia** O.P. Dhungyel*, R.J. Whittington, *The University of Sydney, Australia*	**[B4.1] PLA microspheres induce robust immune responses via several commonly used parenteral administration routes** X.M. Chen, Y. Liu, W.F. Zhang, T.Y. Yang, G.H. Ma, L.Y. Wang*, *Chinese Academy of Sciences, China*
11:55-12:10	**[B3.2] Field trials of the TSOL18 vaccine** E. Assana*[1], C.M. Jayashi[2], M.W. Lightowlers[3], *[1]The University of Ngaoundere, Cameroon, [2]The University of Queensland, Australia, [3]The University of Melbourne, Australia*	**[B4.2] Protective effect of active immunization against IL-6 in mice and monkeys** L. Desallais*[1], H. Mouhsine[1], G. Moreau[2], C. Bouchez[3], H. Do[2], R. Ratsimandresey[2], F. Quintin-Colonna[4], M. Montes[1], J.F. Zagury[1], *[1]Conservatoire National des Arts et Métiers, France, [2]Peptinov, France, [3]CiToxLaB, France, [4]Université Paris Descartes, France*
12:10-12:25	**[B3.3] A novel Porcine Circovirus Type 2 (PCV2) Peptide based vaccine formulated in Silicon Nanoparticles (SiNP)** M.D. Welsh*[1], P. Lagan-Tregaskis[1], S. Doherty[1], N. Torabipour[2], S. Saffie-Siebert[2], J. McKillen[1], M. McMenamy[1], *[1]Agrifood and Biosciences Institute, UK, [2]SiSaf Ltd, UK*	**[B4.3] Immune responses to vaccines involving a combined antigen-nanoparticle mixture and nanoparticle-encapsulated antigen formulation** G.H. Ma, W.F. Zhang, L.Y. Wang*, Z.G. Su, *Chinese Academy of Sciences, China*
12:25-12:40	**[B3.4] Vaccination against Schmallenberg virus: From heterologous Akabane/Aino virus vaccine to inactivated homologous vaccine prototypes** K. Wernike*, S. Hechinger, B. Hoffmann, M. Beer, *Friedrich-Loeffler-Institut, Germany*	**[B4.4] Age-associated defects impair the optimal development of a protective immune response to *Clostridium difficile* in the context of infection and vaccination in an aged murine model** M. Bernui*[1], S. Baliban[1], N. Sardesai[1,2], J. Jacobson[1], D. Weiner[1,3], M. Kutzler[1], *[1]Drexel University College of Medicine, USA, [2]Inovio Pharmaceuticals, USA, [3]University of Pennsylvania School of Medicine, USA*
12:40-14:00	**Lunch** *Room: Grand Ballroom I-III*	
Room	**Garden Room**	
13:00-14:00	Pandemic Vaccine Supply - Challenges and Opportunities from a Raw Materials Perspective N. Khan, *EMD Millipore , USA* Symposium Sponsored by:	
Room	**Borghese Garden/ Salon Venezia**	
14:00-15:00	ISV Annual General Meeting (open)	
15:00-16:00	**Poster Session 2 with refreshments** *Room: Grand Ballroom I-III*	
Room	**Garden Room**	
16:00-18:10	**Plenary Session 4: T cell Based Responses, Cancer Vaccines & Immunotherapy** *Session Chair: Clarisa Beatriz Palatnik-de-Sousa & Niranjan Y. Sardesai* Session Sponsored by:	
16:00-16:20	**[K18] Strategies for Anti-HIV Genetic Engineering** C. June, *University of Pennsylvania, USA*	

16:20-16:40	**[K19] Immunotherapy using stem cell-like T cells for the treatment of advanced cancer** N.P. Restifo, *National Cancer Institute, USA*
16:40-16:55	**[O4.1] Immunoadjuvant IL-33 amplifies memory CD8 T cells and enhances antigen-specific tumor and viral immunity** D.O.V. Villarreal*[1], N.S. Svoronos[1], M.C.W. Wise[1], J.N.W. Walters[1], J.Y. Yan[2], M.P.M. Morrow[1], D.B.W. Weiner[1], *[1]University of Pennsylvania, USA, [2]Inovio Pharmaceuticals, USA*
16:55-17:10	**[O4.2] Induction of robust CD8+ responses and therapeutic antitumor response in mice immunized with HSV-1 gD protein genetically fused with the E7 HPV-16 oncoprotein and poly (I:C)** B.F.M.M. Porchia*[1], D.S. Rosa[2], S.B. Boscardin[1], M.O. Diniz[1], N.S. Sales[1], L.M. Aps[1], L.C.S. Ferreira[1], *[1]University of São Paulo, Brazil, [2]Federal University of São Paulo, Brazil*
17:10-17:25	**[O4.3] Co-expression of tumor antigen and IL-2 from an adenoviral vector significantly improves immunogenicity and therapeutic potential** B.A.H. Jensen, M.A. Steffensen, K.N. Nielsen, J.P. Christensen, P.J. Holst, A.R. Thomsen*, *University of Copenhagen, Denmark*
17:25-17:40	**[O4.4] Treg profiles and vaccine performance** R.D. Bremel*, E.J. Homan, *EigenBio LLC, USA*
17:40-17:55	**[O4.5] Antigen discovery for the identification of vaccine candidates and biomarkers using a T cell driven approach in combination with positional scanning peptide libraries** V.A. Judkowski[1], R.G. Santos[1], G. Acevedo[2], M.A. Giulianotti[1], J.R. Appel[1], S. Longhi[2], K. Gomez[2], C. Pinilla*[1], *[1]Torrey Pines Institute for Molecular Studies, USA, [2]Instituto de Investigaciones en Ingenieria Genetica y Biologia Molecular, Argentina*
17:55-18:10	**[O4.6] Randomized, double-blind, placebo-controlled phase II study results from VGX-3100 HPV specific immunotherapy for Cervical Intraepithelial Neoplasia: Induction of potent HPV specific T-cells and regression of cervical lesions** N. Sardesai*[1], C. Trimble[2], M. Morrow[2], X. Shen[1], M. Dallas[1], D. Weiner[1], J. Boyer[1], *[1]Inovio Pharmaceuticals, USA, [2]Johns Hopkins School of Medicine, USA, [3]University of Pennsylvania Perelman School of Medicine, USA*
19:15-22:15	**Congress Gala Dinner (ticket holders only)** ***@Mitchell Hall, College of Physicians of Philadelphia***
Tuesday, 28 October 2014	
08:00-08:30	Congress Registration
Room	**Garden Room**
08:30-10:35	**Plenary Session 5: Vaccines for Challenging Pathogens** *Session Chair: Klaus Frueh & Ruth Ellis*
08:30-08:55	**[K20] The unique biology, immunology and efficacy of cytomegalovirus-vectored vaccines against chronic and recurring infectious diseases** K. Frueh, *Oregon Health and Science University (OHSU), USA*
08:55-09:20	**[K21] Mucosal routes for immunotherapies against respiratory infections** J.A. Chabalgoity, *University of Uruguay, Uruguay*
09:20-09:35	**[O5.1] Involvement of the AIM2 inflammasome pathway in antigen specific antibody responses elicited by HA-expressing influenza DNA vaccine** J. Suschak*, S. Wang, K.A. Fitzgerald, S. Lu, *University of Massachusetts Medical School, USA*
09:35-09:50	**[O5.2] Innovative proof of concept trials to rationalize clinical development of TB vaccines** R.D. Ellis*[1], D. Tait[2], J. Chappell[1], R. Goldstein[1], T. Evans[1], A.M. Ginsberg[1], *[1]Aeras, USA, [2]Aeras, South Africa*
09:50-10:05	**[O5.3] Removal of Tau Oligomers by immunotherapy ameliorate memory in an Alzheimer's disease mouse model** D.L. Castillo-Carranza*[1,2], M.J. Guerrero-Munoz[1,2], U. Sengupta[1,2], C. Hernandez[1,2], K. Dineley[1,2], R. Kayed[2,3], *[1]University of Texas Medical Branch, USA, [2]Mitchell Center for Neurodegenerative Diseases, USA, [3]Sealy Center for Vaccine Development, USA*
10:05-10:20	**[O5.4] Hepatitis B virus capsid-like particles presenting tick salivary proteins -promising anti-tick vaccine candidates-** P. Kolb*, D. Bentrop, R. Wallich, M. Nassal, *University Hospital, Freiburg, Germany*
10:20-10:35	**[O5.5] Development of a vaccine against heroin**

	G.R. Matyas*[1], K. Rice[2,3], F. Li[2,3], Z. Beck[1,4], J.F.G. Antoline[2,3], K. Cheng[2,3], O. Torres[1,4], R. Jalah[1,4], M.R. Iyer[3], A.E. Jacobson[2,3], *[1]Walter Reed Army Institute of Research, USA, [2]National Institute on Drug Abuse, USA, [3]National Institute on Alcohol Abuse and Alcoholism, USA, [4]Henry M. Jackson Foundation for the Advancement of Military Medicine, USA*	
10:35-11:00	**Refreshment Break** *Room: Grand Ballroom I-III*	
Room	**Garden Room**	**Borghese Garden/ Salon Venezia**
11:00-12:40	**Breakout Session 5: Design and Analysis of Vaccine Antigens** *Session Chair: Annie De Groot & John Hennessey*	**Breakout Session 6: Delivery Mechanisms, Manufacturing, and Safety Issues for Vaccines (Sponsored by the Brighton Collaboration)** *Session Chair: Steven Black & Manon Cox*
11:00-11:20	**[K22] Epitope characterization of recombinant virus-like particle based vaccines** Q. Zhao, *Xiamen University, China*	**[K24] Strategies to combat vaccine hesitancy** D. Salmon, *Johns Hopkins University, USA*
11:20-11:40	**[K23] Discovering and modeling antigen - Antibody: Effector function relationships from multidimensional assays of polyclonal samples** C. Bailey-Kellogg, *Dartmouth College, USA*	**[B6.1] Two Birds with one Stone: Rabies-virus based Ebola Virus Vaccine** M. Schnell, *Thomas Jefferson University, USA*
11:40-11:55	**[B5.1] Systems biology study of molecular signatures of antibody response to influenza A/H1N1 vaccine in older individuals** I.G. Ovsyannikova*, A.L. Oberg, R.B. Kennedy, I.H. Haralambieva, M.T. Zimmermann, K.M. Goergen, D.E. Grill, G.A. Poland, *Mayo Clinic, USA*	**[B6.2] Parental recall of vaccines administered in a school based vaccination program** M.K. Young*[1,2], D. Gray[3], P. Walker[4], J. Chisompola Lubina[5], P. Baker[5], *[1]Griffith University, Australia, [2]Queensland Health, Australia, [3]VaxWorksHealth, Australia, [4]Brisbane City Council, Australia, [5]QUT, Australia*
11:55-12:10	**[B5.2] Pertussis booster vaccine uptake during pregnancy, and associated factors** E.H. Hayles*[1,2], S.C. Cooper[2], N.J. Wood[1,2], S.R. Skinner[2], J.H.K. Sinn[2,3], *[1]National Centre for Immunisation Research and Surveillance, Australia, [2]The University of Sydney, Australia, [3]Royal North Shore Hospital, Australia*	**[K25] Recombinant vaccines made in insect cells** M.M.J. Cox, *Protein Sciences Corporation, USA*
12:10-12:25	**[B5.3] Chlamydial vaccines: Should we target infection or disease?** K.W. Beagley*, C.W. Armitage, C.P. O'Meara, *Queensland University of Technology, Australia*	**[B6.3] Recovery of molecularly-design modular vaccines for low-cost markets** N. Wibowo*, Y. Wu, L.H.L. Lua, A.P.J. Middelberg, *The University of Queensland, Australia*
12:25-12:40	**[B5.4] Preclinical and clinical development of a vaccine for prevention and treatment of fungal infections due to *Candida*** J.P. Hennessey, Jr., *NovaDigm Therapeutics, Inc., USA*	**[B6.4] Development of eilat virus, a host-restricted alphavirus, as a vaccine platform** J. Erasmus*[1], F. Nasar[1], R. Seymour[1], E. Wang[1], G. Leal[1], S. Weaver[1,2], *[1]University of Texas Medical Branch, USA, [2]Sealy Center for Vaccine Development, USA*
12:40-12:55	**[B5.5] Predicting vaccine efficacy: H7N9 influenza case study** A.S. De Groot*[1,4], R. Liu[1], R. Tassone[1], A.H. Gutierrez[1], F. Terry[4], K. Sangare[3], M.A. Arditio[4], C. Bailey-Kellogg[2], W.D. Martin[4], *[1]University of Rhode Island, USA, [2]Dartmouth College, USA, [3]University of Bamako, USA, [4]EpiVax Inc., USA*	**[B6.5] Titer on chip: New analytical tool for influenza vaccine potency determination** K. Rowlen, *InDevR, Inc., USA*
12:55-14:10	**Lunch** *Room: Grand Ballroom I-III*	
Room	**Garden Room**	
13:15-14:00	Vaccine Author Workshop	
14:10-14:15	Edward Jenner Poster Prize Ceremony	

14:15-15:00	**Plenary Session 6: Cost Evaluation of Vaccines** *Session Chair: Ray Spier*
14:15-14:30	**[K26] The risks of using cost effectiveness analyses for decision making regarding vaccine development and introduction** S. Black, *Center for Global Health Cincinnati Children's Hospital, USA*
14:30-14:45	**[K27] The Impending Crisis for Vaccine R & D** S. Plotkin[1,2], *[1]University of Pennsylvania, USA, [2]Vaxconsult, USA*
14:45-15:00	**[K28] Risk, vaccination and the human mind** R. Spier, *The International Society for Vaccines, UK*
15:00-15:15	**Question and answer and discussion session on cost evaluation of vaccines**
15:15-15:45	**Plenary Session 7: Closing Keynotes – Considerations for Future Directions in Vaccine Development** *Session Chair: Ted M. Ross*
15:15-15:45	**[K30] The status of vaccine development against cytomegalovirus** S.A. Plotkin, *University of Pennsylvania, USA*
15:45-16:00	**Closing Summary:** Adolfo Garcia-Sastre and Ted M. Ross, *Congress Co-Chairs*